Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/27/03 → 2/28/05 |
Funding
- Johnson and Johnson: $23,837.00
A Phase 2 Study of ET-743 as Second-Line Therapy in Subjects With Persistent or Recurrent Endometrial Carcinoma
- Ueland, Frederick (PI)